Otero Jose Manuel's Form 4/A amendment
AmendedLexeo Therapeutics, Inc.LXEO · filed Feb 20, 2026
- Accession no.
- 0002024096-26-000004
- Filed
- Feb 20, 2026
- Trade date
- Nov 18, 2025
- Filing delay
- 94 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Nov 20, 2025
This filing lists 1 non-derivative transaction. Open-market sales total $6.68K. It was filed 94 days after the trade.
This amendment replaces 0002024096-25-000005 (filed Nov 20, 2025).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Otero Jose ManuelCIK 0002024096 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | Common Stock | SSaleDisposed | −721 | $9.27F3 | −$6,683.67 | 63,476 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On November 20, 2025, the reporting person filed a Form 4 which inadvertently reported that a sale to cover tax obligations occurred on August 18, 2025. In fact, as reported in this amendment, the sale occurred on November 18, 2025.
- F2
Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
- F3
This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
Includes 47,733 RSUs.